A new focus area for cell therapy developers is emerging around shifting manufacturing systems earlier toward GMP-compatible, scalable workflows. The thrust is to transition from research-grade processes to closed automated systems and chemically defined media that are designed to clear regulatory hurdles and avoid expensive comparability studies. By emphasizing automation, closed manufacturing, and defined inputs, the approach aims to reduce variability across batches—one of the key issues that can complicate late-stage scale-up. For sponsors building programs from early development into clinical and commercial pathways, the manufacturing roadmap is increasingly treated as a regulatory asset. The development is also a reminder that manufacturing decisions can determine timelines: designing for GMP and comparability from the start can shorten iteration cycles when programs move toward pivotal trials and commercial filings.